Litcius/Paper detail

New advances in novel pharmacotherapeutic candidates for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) between 2022 and 2024

Shu Wei Wong, Yong‐Yu Yang, Hui Chen, Li Xie, Xizhong Shen, Ning‐Ping Zhang, Jian Wu

2025Acta Pharmacologica Sinica10 citationsDOIOpen Access PDF

Topics & Concepts

SteatohepatitisNonalcoholic steatohepatitisMedicineInternal medicineFatty liverDiseaseNonalcoholic fatty liver diseaseLiver Disease Diagnosis and TreatmentDiet, Metabolism, and DiseasePancreatic function and diabetes
New advances in novel pharmacotherapeutic candidates for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) between 2022 and 2024 | Litcius